Journal of Scleroderma and Related Disorders, published by SAGE Publications Ltd, stands as a key platform dedicated to advancing the understanding of scleroderma and related autoimmune disorders. With its ISSN of 2397-1983 and E-ISSN of 2397-1991, this esteemed journal has been contributing to the field since its inception in 2016 and continues to attract attention with its convergence period extending to 2024. The journal operates with an open access policy, thus enhancing the visibility and accessibility of research findings for healthcare professionals, researchers, and students worldwide. Recognized for its significant impact, it holds a Q3 quartile ranking in Immunology and Q2 rankings in Immunology and Allergy and Rheumatology in 2023, showcasing its relevance in these critical fields. Furthermore, the journal has achieved commendable Scopus rankings, positioning it firmly within the top echelons of its categories, particularly in Medicine - Rheumatology (#33/73, 55th percentile). With its comprehensive scope, the Journal of Scleroderma and Related Disorders plays a pivotal role in disseminating vital research that can influence treatment strategies and improve patient care for those suffering from scleroderma and its related conditions.

Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.

Rheumatology and Therapy, published by Springer, stands as a prominent open-access journal within the fields of Immunology and Allergy and Rheumatology. Since its inception in 2014, the journal has made significant contributions to advancing the understanding, diagnosis, and treatment of rheumatic diseases, garnering a solid reputation with an impact factor that reflects its rigorous peer-review process and scholarly influence. Currently ranked in the Q2 quartile for both its categories according to 2023 metrics, it occupies a significant position among its peers, standing at Rank #21 out of 73 in Medicine Rheumatology and Rank #101 out of 233 for Medicine Immunology and Allergy. The journal's scope encompasses cutting-edge research, reviews, and clinical studies that aim to bridge the gap between laboratory findings and patient care, making it an invaluable resource for researchers, clinicians, and students alike. With its commitment to open access, Rheumatology and Therapy ensures that high-quality research is available to a global audience, fostering collaboration and innovation in rheumatology and immunology. To learn more, visit their official site and explore the wealth of knowledge available.

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.

Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders, published by SAGE PUBLICATIONS LTD, is an esteemed open-access journal dedicated to advancing knowledge in the field of rheumatology and related immunological disorders. Since its inception in 2008, the journal has provided a platform for researchers and clinicians from around the world to disseminate cutting-edge studies and insights into arthritis and musculoskeletal conditions. Based in New Zealand, this journal has maintained a commendable standing in academic circles, evidenced by its Q3 quartile rankings in both Immunology and Allergy and Rheumatology categories for 2023, alongside respectable Scopus rankings. The journal serves as a vital resource for healthcare professionals, researchers, and students, facilitating enhanced understanding and treatment of musculoskeletal disorders through high-quality research and peer-reviewed articles. With a focus on fostering interdisciplinary collaboration and innovation in the field, Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is essential reading for those committed to improving patient outcomes and advancing scientific knowledge.

The Lancet Rheumatology, published by Elsevier, is a premier academic journal dedicated to advancing the understanding of rheumatology and immunological diseases. Launched in 2019, this esteemed publication has quickly become a leading source of research, achieving an impressive Q1 ranking in both the fields of Rheumatology and Immunology as of 2023. With Scopus rankings placing it at #2 out of 73 in Medicine - Rheumatology and #6 out of 233 in Medicine - Immunology and Allergy, the journal serves as an essential platform for disseminating high-quality, peer-reviewed articles that address the latest findings and clinical practices in these domains. The journal, accessible in print and online, is committed to fostering knowledge and collaboration among researchers, healthcare professionals, and students alike, making it an invaluable resource for those seeking to deepen their expertise in rheumatology and its interrelated fields.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.